Zoetis Inc. $ZTS Shares Sold by Destination Wealth Management

Posted by Francis Steltz on Jun 14th, 2026

Destination Wealth Management reduced its stake in shares of Zoetis Inc. (NYSE:ZTS – Free Report) by 23.4% during the 4th quarter, Holdings Channel.com reports. The firm owned 103,874 shares of the company’s stock after selling 31,738 shares during the quarter. Destination Wealth Management’s holdings in Zoetis were worth $13,069,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in ZTS. Nordea Investment Management AB boosted its stake in shares of Zoetis by 79.2% during the 4th quarter. Nordea Investment Management AB now owns 4,932,787 shares of the company’s stock worth $622,222,000 after acquiring an additional 2,179,578 shares in the last quarter. Seilern Investment Management Ltd boosted its stake in shares of Zoetis by 361.2% during the 4th quarter. Seilern Investment Management Ltd now owns 333,465 shares of the company’s stock worth $41,957,000 after acquiring an additional 261,155 shares in the last quarter. Assenagon Asset Management S.A. boosted its stake in shares of Zoetis by 134.4% during the 4th quarter. Assenagon Asset Management S.A. now owns 1,631,619 shares of the company’s stock worth $205,290,000 after acquiring an additional 935,432 shares in the last quarter. Pincus Capital Management LP purchased a new stake in shares of Zoetis during the 4th quarter worth about $2,109,000. Finally, Prudential PLC boosted its stake in shares of Zoetis by 17.7% during the 3rd quarter. Prudential PLC now owns 197,852 shares of the company’s stock worth $28,950,000 after acquiring an additional 29,702 shares in the last quarter. 92.80% of the stock is owned by institutional investors and hedge funds.

Zoetis Trading Down 2.3%

ZTS stock opened at $79.51 on Friday. The company has a current ratio of 3.15, a quick ratio of 1.91 and a debt-to-equity ratio of 2.80. Zoetis Inc. has a 12-month low of $72.38 and a 12-month high of $167.38. The stock has a market cap of $33.33 billion, a price-to-earnings ratio of 13.19, a PEG ratio of 1.24 and a beta of 0.75. The business’s 50-day moving average is $96.94 and its 200 day moving average is $114.22.

Zoetis (NYSE:ZTS – Get Free Report) last posted its quarterly earnings data on Thursday, May 7th. The company reported $1.53 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.60 by ($0.07). Zoetis had a return on equity of 66.85% and a net margin of 27.80%.The firm had revenue of $2.26 billion during the quarter, compared to analyst estimates of $2.30 billion. During the same quarter in the previous year, the firm posted $1.48 earnings per share. The company’s quarterly revenue was up 2.9% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. On average, sell-side analysts anticipate that Zoetis Inc. will post 6.88 EPS for the current fiscal year.

Zoetis Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Monday, July 20th will be issued a $0.53 dividend. This represents a $2.12 annualized dividend and a yield of 2.7%. The ex-dividend date is Monday, July 20th. Zoetis’s payout ratio is presently 35.16%.

Key Headlines Impacting Zoetis

Here are the key news stories impacting Zoetis this week:

Positive Sentiment: The recent analyst coverage split suggests some Wall Street firms still see value in Zoetis despite the recent selloff, which could help stabilize sentiment. Zoetis (ZTS) Stock Draws Fresh Price Target Split After Difficult Q1 Update
Neutral Sentiment: Multiple law firms are urging investors who bought Zoetis shares between January 14, 2025 and May 6, 2026 to join or lead securities-fraud litigation ahead of the July 27 deadline; while procedural for now, the steady stream of notices keeps legal overhang in focus. Zoetis Inc. (ZTS) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Neutral Sentiment: Additional class-action reminders from The Gross Law Firm, Bragar Eagel & Squire, and The Schall Law Firm add to the headline noise, but do not yet change Zoetis’s fundamentals on their own. ZTS Shareholder Alert: Zoetis Inc. Securities Class Action Lawsuit
Neutral Sentiment: The lawsuits appear to center on alleged misrepresentations about weakening veterinarian adoption and prescription trends, which help explain why investors remain cautious after the company’s disappointing Q1 results. Lost Money on Zoetis Inc. (ZTS)? Join Class Action Suit Seeking Recovery
Negative Sentiment: The legal overhang and repeated fraud allegations are a negative for sentiment and may keep pressure on Zoetis Inc. (NYSE: ZTS) until there is more clarity on the lawsuits and on whether the underlying business trends are improving. ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Zoetis Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ZTS

Insider Buying and Selling

In other news, Director Frank A. Damelio acquired 6,650 shares of the stock in a transaction that occurred on Wednesday, May 13th. The shares were bought at an average cost of $75.39 per share, for a total transaction of $501,343.50. Following the acquisition, the director owned 21,458 shares in the company, valued at approximately $1,617,718.62. This represents a 44.91% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Paul Bisaro bought 2,000 shares of the firm’s stock in a transaction on Wednesday, May 13th. The stock was acquired at an average cost of $75.88 per share, for a total transaction of $151,760.00. Following the completion of the purchase, the director directly owned 27,862 shares in the company, valued at approximately $2,114,168.56. This represents a 7.73% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last three months, insiders have bought 11,650 shares of company stock worth $886,384. Insiders own 0.22% of the company’s stock.

Analysts Set New Price Targets

ZTS has been the topic of several recent analyst reports. Argus reissued a “hold” rating on shares of Zoetis in a research note on Wednesday, May 27th. Wall Street Zen lowered shares of Zoetis from a “buy” rating to a “hold” rating in a research note on Saturday, May 2nd. Weiss Ratings lowered shares of Zoetis from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Friday, March 27th. William Blair reissued an “outperform” rating on shares of Zoetis in a research note on Monday, March 2nd. Finally, BTIG Research reissued a “buy” rating and set a $160.00 target price on shares of Zoetis in a research note on Thursday, February 26th. Six analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Zoetis presently has an average rating of “Hold” and an average target price of $133.92.

View Our Latest Stock Report on Zoetis

Zoetis Profile

(Free Report)

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.